IL109350A - Stable liquid preparations of gamma interferon - Google Patents

Stable liquid preparations of gamma interferon

Info

Publication number
IL109350A
IL109350A IL10935094A IL10935094A IL109350A IL 109350 A IL109350 A IL 109350A IL 10935094 A IL10935094 A IL 10935094A IL 10935094 A IL10935094 A IL 10935094A IL 109350 A IL109350 A IL 109350A
Authority
IL
Israel
Prior art keywords
ifn
composition
phenol
isotonifier
benzyl alcohol
Prior art date
Application number
IL10935094A
Other languages
English (en)
Hebrew (he)
Other versions
IL109350A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL109350A0 publication Critical patent/IL109350A0/xx
Publication of IL109350A publication Critical patent/IL109350A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL10935094A 1993-05-12 1994-04-19 Stable liquid preparations of gamma interferon IL109350A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6032793A 1993-05-12 1993-05-12

Publications (2)

Publication Number Publication Date
IL109350A0 IL109350A0 (en) 1994-07-31
IL109350A true IL109350A (en) 2001-01-28

Family

ID=22028807

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10935094A IL109350A (en) 1993-05-12 1994-04-19 Stable liquid preparations of gamma interferon

Country Status (23)

Country Link
EP (1) EP0697887B1 (xx)
JP (1) JP4053586B2 (xx)
KR (1) KR100330325B1 (xx)
CN (1) CN1120724C (xx)
AT (1) ATE173632T1 (xx)
AU (1) AU683469B2 (xx)
CA (1) CA2159602C (xx)
CZ (1) CZ285389B6 (xx)
DE (1) DE69414841T2 (xx)
DK (1) DK0697887T3 (xx)
ES (1) ES2126114T3 (xx)
FI (1) FI111442B (xx)
GR (1) GR3029286T3 (xx)
HK (1) HK1008303A1 (xx)
HU (1) HUT72980A (xx)
IL (1) IL109350A (xx)
NO (1) NO320069B1 (xx)
NZ (1) NZ266354A (xx)
PL (1) PL176079B1 (xx)
SK (1) SK280958B6 (xx)
TW (1) TW275585B (xx)
WO (1) WO1994026302A1 (xx)
ZA (1) ZA942955B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
US6964947B1 (en) 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
AU721112B2 (en) * 1995-11-07 2000-06-22 Genentech Inc. Stabilizing formulation for NGF
JP3493866B2 (ja) * 1995-12-27 2004-02-03 ライオン株式会社 発泡性口腔用組成物
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
CA2259927A1 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
ES2224290T5 (es) * 1996-12-24 2012-03-12 Biogen Idec Ma Inc. Formulaciones l�?quidas estables de interferón.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU4445201A (en) * 2000-03-30 2001-10-08 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
EP1516627A1 (en) * 2003-09-17 2005-03-23 CONARIS research institute AG Interferon-Gamma for the treatment of diseases associated with the NOD2 gene
JP5137055B2 (ja) * 2006-03-10 2013-02-06 塩野義製薬株式会社 安定化されたインターフェロン−γ組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257956B2 (en) * 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation

Also Published As

Publication number Publication date
CA2159602A1 (en) 1994-11-24
CA2159602C (en) 2008-08-26
CZ295595A3 (en) 1996-04-17
FI955136A0 (fi) 1995-10-27
NO320069B1 (no) 2005-10-17
PL311639A1 (en) 1996-03-04
CN1120724C (zh) 2003-09-10
WO1994026302A1 (en) 1994-11-24
NO954544L (no) 1995-11-10
DK0697887T3 (da) 1999-08-09
KR100330325B1 (ko) 2002-11-01
DE69414841T2 (de) 1999-06-02
NZ266354A (en) 1997-06-24
CN1122575A (zh) 1996-05-15
IL109350A0 (en) 1994-07-31
EP0697887A1 (en) 1996-02-28
TW275585B (xx) 1996-05-11
HU9503223D0 (en) 1996-01-29
SK137895A3 (en) 1997-02-05
AU6782294A (en) 1994-12-12
JPH08510242A (ja) 1996-10-29
SK280958B6 (sk) 2000-10-09
ATE173632T1 (de) 1998-12-15
HUT72980A (en) 1996-06-28
NO954544D0 (no) 1995-11-10
PL176079B1 (pl) 1999-04-30
DE69414841D1 (de) 1999-01-07
KR960702320A (ko) 1996-04-27
HK1008303A1 (en) 1999-05-07
ES2126114T3 (es) 1999-03-16
FI955136A (fi) 1995-10-27
AU683469B2 (en) 1997-11-13
EP0697887B1 (en) 1998-11-25
ZA942955B (en) 1995-10-30
GR3029286T3 (en) 1999-05-28
JP4053586B2 (ja) 2008-02-27
CZ285389B6 (cs) 1999-07-14
FI111442B (fi) 2003-07-31

Similar Documents

Publication Publication Date Title
EP0697887B1 (en) Stable liquid compositions of gamma interferon
AU2005249233B2 (en) Stabilized interferon liquid formulations
EP1417972B2 (en) Stabilized teriparatide solutions
KR101084412B1 (ko) 코팅된 제약 용기 내 안정화된 액상 단백질 제제
JP5346065B2 (ja) Ｈｓａを含まない安定なインターフェロン液体製剤
EA002754B1 (ru) Устойчивые жидкие составы интерферона
US20030049277A1 (en) Composition for treatment of and method of monitoring hepatitis C virus using interferon-TAU
US11207411B2 (en) Stabilized preparation of interferon beta variant
AU2005200879B2 (en) GRF-containing lyophilized pharmaceutical compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired